Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AXT-2003
- Development stage
- Preclinical
- Lead developer
- Axter Therapeutics
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
AXT-2003 is a preclinical-stage small molecule combination therapy being developed by Axter Therapeutics for the treatment of prostate cancer. The drug candidate combines an EZH2 (Enhancer of zeste homolog 2) inhibitor with an androgen receptor (AR) inhibitor. This dual-mechanism approach aims to suppress complementary growth pathways in prostate cancer cells, potentially addressing resistance to standard androgen deprivation therapies. EZH2 is an epigenetic enzyme that promotes cancer progression and lineage plasticity, while the androgen receptor is the primary driver of prostate cancer growth.
Beyond the preview
Go deeper on AXT-2003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AXT-2003.